Overview
Join us as members of the IASLC Education Committee moderate the program and lead discussions, including a Q&A session, following panel presentations by Tetsuya Mitsudomi, MD, PhD, Feifei Huang, RN, PhD, and Matthew Smeltzer, PhD. The event will cover key topics and provide a summary of the insightful presentations from the 2024 IASLC Asia Conference on Lung Cancer (ACLC).
At the end of the webinar, learners will be able to:
- Implement neoadjuvant nivolumab & chemotherapy treatment for resectable NSCLC from Checkmate 816 Asian subpopulation from the 4-year update to better manage this group of patients.
- Optimize the use of biomarker testing in Asia with reference to the IASLC Global Survey on Biomarker Testing in Asia results.
- Understand the feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an artificial intelligence-based diagnostic system, particularly in underserved populations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
At the end of the webinar, learners will be able to:
- Implement neoadjuvant nivolumab & chemotherapy treatment for resectable NSCLC from Checkmate 816 Asian subpopulation from the 4-year update to better manage this group of patients.
- Optimize the use of biomarker testing in Asia with reference to the IASLC Global Survey on Biomarker Testing in Asia results.
- Understand the feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an artificial intelligence-based diagnostic system, particularly in underserved populations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Feifei Huang
RN, PhD
Professor
Fujian Medical University School of Nursing
Matthew Smeltzer
PhD, MStat
Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health
University of Memphis
